KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Interest Expenses (2016 - 2023)

Historic Interest Expenses for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Q2 2023 value amounting to $910000.0.

  • Supernus Pharmaceuticals' Interest Expenses fell 4972.38% to $910000.0 in Q2 2023 from the same period last year, while for Mar 2024 it was $910000.0, marking a year-over-year decrease of 8628.07%. This contributed to the annual value of $2.4 million for FY2023, which is 6584.16% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Interest Expenses of $910000.0 as of Q2 2023, which was down 4972.38% from $1.5 million recorded in Q1 2023.
  • Supernus Pharmaceuticals' Interest Expenses' 5-year high stood at $6.1 million during Q1 2021, with a 5-year trough of $910000.0 in Q2 2023.
  • For the 5-year period, Supernus Pharmaceuticals' Interest Expenses averaged around $4.4 million, with its median value being $5.7 million (2019).
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Interest Expenses skyrocketed by 71868.9% in 2019, and later crashed by 7313.78% in 2022.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Interest Expenses stood at $5.8 million in 2019, then rose by 5.52% to $6.1 million in 2020, then dropped by 2.66% to $5.9 million in 2021, then tumbled by 73.14% to $1.6 million in 2022, then tumbled by 42.91% to $910000.0 in 2023.
  • Its Interest Expenses stands at $910000.0 for Q2 2023, versus $1.5 million for Q1 2023 and $1.6 million for Q4 2022.